Post-Market Study of Low-flow ECCO2R Using PrismaLung+

Exclusion Criteria

• •1. Patients body weight \< 30 kg
• •2. Patients with a contraindication for systemic anticoagulation with heparin
• •3. Patients with a platelet count \< 50,000/µL
• •4. Patients on MV \> 7 days
• •5. Patients with very severe, or stage 4 (as per GOLD staging System) chronic obstructive pulmonary disease (COPD)
• •6. Current or history of heparin-induced thrombocytopenia
• •7. Patients who are pregnant and/or breastfeeding
• •8. Patients not expected to survive the duration of the planned study treatment period (24 hours)
• •9. Patients currently participating in another interventional clinical study, except if the patient is in an investigational medicinal product study, already in follow-up without further administration of study drug, and has not received any investigational medicinal product within 5 half-lives